The pooled estimates varied by medication. Lean mass accounted for roughly 25% to 35% of total weight lost [2]. Semaglutide sat at 35.2%, liraglutide at 26.8%, tirzepatide at 25.4%. Changes in overall fat and lean mass do not establish what happens to lipedema-specific fat or symptoms. That condition has a separate and much thinner evidence base.
The pooled estimate for lifestyle intervention alone was 26.2%. The analysis found no statistically significant difference from incretin therapy (p=0.42) [2]. Our guide to lean mass and muscle explains what body composition scans measure.
Lean mass accounted for 17.5% of weight lost in the studies of lifestyle intervention plus resistance training [2]. A separate randomized trial enrolled 120 adults taking tirzepatide. Over 40 weeks, the resistance exercise group lost 1.09 kg less lean soft tissue than the usual-activity group (95% CI 0.43 to 1.75 kg) [4]. Lean soft tissue includes tissues besides skeletal muscle.
A narrative review proposed tailored resistance exercise during incretin treatment to help preserve lean mass [1]. The randomized tirzepatide trial tested that approach in a specific group of adults. Ask your care team whether that evidence applies to your health and activity level.
How to read lean mass results
If you compete under anti-doping rules, our guide to GLP-1 drugs in sport explains what to check with your governing body. An exercise study does not determine which substances are permitted in competition.
A separate meta-analysis examined absolute changes in body composition in adults without type 2 diabetes [3]. Our explanation of lean mass in kilograms and as a share of weight lost shows why the two measures can give different impressions. Neither measure by itself tells you how someone’s strength changed.
What the program price covers
Use the monthly cost guide to compare published medication and care prices. Ask what the quote includes and whether any exercise support requires a separate payment.